Proton Therapy Well-Tolerated for Low-Grade Gliomas
the Cancer Therapy Advisor take:
Patients with low-grade glioma were found to tolerate proton radiation therapy without difficultly, according to an article published online in the journal Cancer.
The study included 20 patients diagnosed with World Health Organization grade 2 glioma. These 20 patients were determined to be eligible for proton radiation therapy at a dose of 54 Gy (relative biological effectiveness) in 30 fractions.
Results revealed that a small subset (6 patients) experienced new neuroendocrine dysfunction and 19 out of the 20 patients received direct irradiation of the hypothalamic-pituitary axis. Overall, intellectual functioning was reported to be within normal range and remained stable over time. Patients’ visuospatial ability, attention/working memory, and executive functioning were all within normal range as well. Impairments were observed in eight patients regarding their neurocognitive functions of language, memory, and processing speed.
However, there was no overall decline in patients’ cognitive functioning reported. Furthermore, patient quality of life assessment remained constant over time. At 3 years, the progression-free survival rate was 85%, while at 5 years it declined to 40%.
Patients with low-grade glioma were found to tolerate proton radiation therapy without difficultly.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy